Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good activity, but side effects may limit its use.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
Cabometyx is the third liver cancer drug approved in the past six months.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.